• Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference

    Источник: Nasdaq GlobeNewswire / 05 мар 2024 07:00:00   America/Chicago

    CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will present a corporate overview at the Leerink Partners Global Biopharma Conference, being held in Miami, FL on Wednesday, March 13, 2024 at 9:20 a.m. ET. Management will also participate in one-on-one investor meetings.

    The webcast of the presentation will be accessible here and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.

    About Fulcrum Therapeutics
    Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir (formerly known as FTX-6058), a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

    Contact:
    Chris Calabrese
    LifeSci Advisors, LLC
    ccalabrese@lifesciadvisors.com
    917-680-5608


    Primary Logo

Опубликовать